Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 4, 2024
Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and AgingAbigail Baim-Lance, Sarah Cooley, Moka Yoo-Jeong, et al.
Plos One|May 30, 2009
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivoAthe M N Tsibris, Bette Korber, Ramy Arnaout, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2007
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjectsNimalie D Stone, Shelia B Dunaway, Charles Flexner, et al.
Pharmaceutics|July 29, 2023
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle FormulationsPaul Curley, James J Hobson, Neill J Liptrott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting TreatmentsEthel D Weld, Jacqueline Astemborski, Gregory D Kirk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
AIDS Research and Human Retroviruses|March 4, 2016
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1Jeffrey M Jacobson, Steven E Bosinger, Minhee Kang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 CountriesN Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusVincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 4, 2024
Current Challenges, Solutions, and Novel Directions in Research and Clinical Care: Proceedings From the 14th Annual International Workshop on HIV and AgingAbigail Baim-Lance, Sarah Cooley, Moka Yoo-Jeong, et al.
Plos One|May 30, 2009
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivoAthe M N Tsibris, Bette Korber, Ramy Arnaout, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2007
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjectsNimalie D Stone, Shelia B Dunaway, Charles Flexner, et al.
Pharmaceutics|July 29, 2023
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle FormulationsPaul Curley, James J Hobson, Neill J Liptrott, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2021
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting TreatmentsEthel D Weld, Jacqueline Astemborski, Gregory D Kirk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.
AIDS Research and Human Retroviruses|March 4, 2016
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1Jeffrey M Jacobson, Steven E Bosinger, Minhee Kang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 CountriesN Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusVincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Pageof 14